| Entry |
|
|---|
| Name |
Trastuzumab (USAN/INN);
Trastuzumab (genetical recombination) (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN);
Trastuzumab-pkrb;
Trastuzumab-anns;
Trastuzumab-dkst;
Trastuzumab-dttb;
Trastuzumab-qyyp;
Trastuzumab-anns;
Herceptin (TN);
Herzuma (TN);
Kanjinti (TN);
Ogivri (TN);
Ontruzant (TN) |
|---|
| Product |
|
|---|
| Sequence |
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY
ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPG
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H147-H203, H264-H324, H370-H428, H229-H'229, H232-H'232, L23-L88, L134-L194, H223-L214) |
|---|
| Type |
Peptide |
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (mixture): | D11560<US> D11934<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody |
|---|
| Disease |
Breast cancer (HER2 overexpressing) [DS: H00031] Breast cancer (ER/ PR negative) [DS: H00031] Gastric cancer (HER2 overexpressing) [DS: H00018] |
|---|
| Type |
Monoclonal antibody |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Network |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01FD01 Trastuzumab
D03257 Trastuzumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Anti-HER2 Antibodies
Trastuzumab
D03257 Trastuzumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D03257 Trastuzumab (USAN/INN); Trastuzumab (genetical recombination) (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
D03257 Trastuzumab
Drug classes [BR:br08332]
Antineoplastic
DG03158 HER2 inhibitor
D03257 Trastuzumab
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
D03257 Trastuzumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03257
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03257
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D03257
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
